Over a week ago |
On The Fly
| ShowHide Related Items >><< - 07/27/22
- Spirit Airlines announces termination of merger agreement with Frontier
- 07/15/22
- ISS formally recommends Spirit shareholders vote against Frontier transaction
- 07/15/22
- ISS formally recommends Spirit shareholders vote against Frontier transaction
- 07/13/22
- JetBlue CEO says 'standing ready' to enter binding merger agreement with Spirit
- $46.56 /
+5.185 (+12.53%) - 07/06/22
- TransMedics director sells $1.7M in common stock
- 04/28/22
- TransMedics receives FDA PMA approval of OCS DCD Heart System
- 02/24/22
- TransMedics Group trading resumes
- 02/24/22
- TransMedics Group trading halted, volatility trading pause
- 08/04/22
- Tilray's Breckenridge Distillery announces two new Mile High Bourbon Blends
- 08/03/22
- Tilray announces US distribution agreement with Southern Glazer's Wine & Spirit
- 07/19/22
- Tilray Medical launches cannabis education platform 'WeCare-MedicalCannabis'
- 07/14/22
- Tilray announces 'Wild West' lineup from CANACA brand
- 07/28/22
- Cathie Wood's ARK Investment bought 408K shares of Teladoc today
- 07/25/22
- Teladoc appoints Waters as COO
- 07/21/22
- Teladoc down 9% after Amazon agrees to acquire One Medical
- 07/15/22
- Teladoc releases new findings on integrated chronic care solutions
- 08/04/22
- Shake Shack sees FY22 domestic company-operated openings 35-40
- 07/13/22
- Chairman of Shake Shack Daniel Meyer buys over $831K in shares
- 02/18/22
- Shake Shack falls -11.3%
- 02/17/22
- Shake Shack drops 9% to $68.49 after Q1 revenue guidance misses estimates
RXRX Recursion Pharmaceuticals - 07/21/22
- Recursion Pharmaceuticals granted EU orphan drug designation for REC-4881
- 06/20/22
- Recursion announces initiation of Phase 2/3 trial for NF2-Mutated Meningiomas
- 04/11/22
- Recursion Pharmaceuticals granted FDA Fast Track designation for REC-4881
- 03/18/22
- Recursion Pharmaceuticals enrolls first patient in Phase 2 SYCAMORE trial
- 08/03/22
- Paramount+ to launch as a Premium Subscription within Roku Channel
- 07/28/22
- Roku drops 25% to $63.40 after Q2 results, Q3 guidance miss estimates
- 07/26/22
- Cathie Wood's ARK Investment bought 585K shares of Roku today
- 06/23/22
- Crackle launches updated app on Roku devices
- 07/28/22
- Royal Caribbean actively managing inflationary pressures
- 07/28/22
- Royal Caribbean has returned to typical booking, cancellation policies
- 07/28/22
- Royal Caribbean: Cruise interest 'basically back to 2019 levels'
- 07/28/22
- Royal Caribbean expects to report a net loss in 2H22
- 06/15/22
- Proterra announces appointment of Hauser to board of directors
- 05/25/22
- Proterra announces Canada's BC Transit approved $20M contract
- 05/13/22
- Soros buys Lucid, exits GM in Q1
- 04/19/22
- Proterra appoints Julian Soell as president of Proterra Transit
- 07/21/22
- NOAA contracts with Planet to gain 'situational awareness' of oil spills debris
- 07/19/22
- Planet Labs completes pilot program with Organic Valley
- 07/13/22
- Planet Labs Germany expands collaboration with BKG
- 06/15/22
- Planet Labs falls -17.6%
- 08/03/22
- Ping Identity rises 59.9%
- 08/03/22
- Ping Identity rises 59.5%
- 08/03/22
- Ping Identity rises 59.9%
- 08/03/22
- Ping Identity to be acquired by Thoma Bravo for $2.8B or $28.50 per share
- 07/15/22
- NexGen Energy announces CNSC acceptance of EIS submission
- 06/21/22
- NexGen Energy announces Rook I Project EIS
- 04/25/22
- NexGen Energy signs IBA with Clearwater River Dene Nation for Rook I Project
- 03/01/22
- NexGen Energy uplists to NYSE from NYSE American
- 07/18/22
- Natera says Federal Circuit affirms September 2021 decision on CareDx patents
- 07/18/22
- Medicare extends coverage of Natera's Signatera MRD test
- 07/14/22
- Natera selected for UnitedHealthcare's Preferred Laboratory Network
- 05/24/22
- Natera appoints Minetta Liu as Chief Medical Officer of oncology
IRT Independence Realty Trust - 05/19/22
- Independence Realty Trust to replace Mimecast in S&P 400 at open on 5/19
- 05/18/22
- Independence Realty Trust announces $250M stock buyback, boosts dividend 17%
DWAC Digital World Acquisition - 07/07/22
- Truth Social denies Donald Trump left board of Trump Media
- 07/01/22
- Trump Media & Technology Group says 'expanding and enhancing Truth Social'
- 06/27/22
- Trump Media issues statement on Digital World Acquisition Corp. SEC filing
- 06/27/22
- Digital World Acquisition says Garelick to resign from board
- 06/14/22
- Compass Inc trading resumes
- 06/14/22
- Compass to eliminate about 10% of current workforce
- 06/14/22
- Compass Inc trading halted, news pending
- 05/12/22
- Compass announces changes to executive structure and strategic plan
- 08/04/22
- Carnival upgrading global fleet with fuel- and energy-saving technology
- 08/01/22
- Carnival welcomes 3M guests since restart of guest operations in July 2021
- 07/21/22
- Carnival falls -11.8%
- 07/21/22
- Carnival falls -13.6%
- 08/03/22 Citi
- Roku price target lowered to $125 from $165 at Citi
- 08/01/22 Morgan Stanley
- Roku price target lowered to $55 from $80 at Morgan Stanley
- 07/29/22 BofA
- BofA double downgrades Roku with headwinds seen lasting 2-3 quarters
- 07/29/22 BofA
- Roku downgraded to Underperform from Buy at BofA
- 07/19/22 Gordon Haskett
- Shake Shack initiated with a Hold at Gordon Haskett
- 07/18/22 Morgan Stanley
- Shake Shack price target lowered to $48 from $63 at Morgan Stanley
- 07/13/22 Cowen
- Shake Shack price target lowered to $52 from $70 at Cowen
- 07/08/22 Wedbush
- Wedbush sees Dine Brands, Wingsstop, Wendy's as Best Ideas in restaurants
- 07/29/22 Wells Fargo
- Royal Caribbean price target lowered to $58 from $81 at Wells Fargo
- 07/29/22 Deutsche Bank
- Royal Caribbean price target lowered to $48 from $50 at Deutsche Bank
- 07/29/22 Susquehanna
- Royal Caribbean price target lowered to $50 from $70 at Susquehanna
- 06/29/22 Barclays
- Barclays initiates cruise line space with Royal Caribbean top pick
- 07/22/22 Truist
- Carnival price target lowered to $8 from $15 at Truist
- 07/21/22 Stifel
- Carnival selloff 'coming for sure' as equity raise will cause panic, says Stifel
- 07/04/22 HSBC
- HSBC says too early to call inflection point for Carnival
- 06/29/22 Morgan Stanley
- Morgan Stanley cuts Carnival price target to $7, sees bear case of zero
- 08/04/22 DA Davidson
- Ping Identity downgraded to Neutral from Buy at DA Davidson
- 08/04/22 Stephens
- Ping Identity downgraded to Equal Weight from Overweight at Stephens
- 08/04/22 Barclays
- Ping Identity downgraded to Equal Weight from Overweight at Barclays
- 08/04/22 BTIG
- Ping Identity downgraded to Neutral from Buy at BTIG
- 07/21/22 Morgan Stanley
- Compass downgraded to Equal Weight from Overweight at Morgan Stanley
- 05/16/22 Oppenheimer
- Compass price target lowered to $9 from $14 at Oppenheimer
- 04/22/22 Zelman
- Compass initiated with a Hold at Zelman
- 03/30/22 Goldman Sachs
- Compass price target lowered to $12 from $21 at Goldman Sachs
DWAC Digital World Acquisition RXRX Recursion Pharmaceuticals - 04/18/22 BofA
- Recursion Pharmaceuticals downgraded to Neutral from Buy at BofA
- 03/04/22 SVB Securities
- Recursion Pharmaceuticals downgraded to Market Perform from Outperform at SVB Leerink
- 09/21/21 Berenberg
- Recursion Pharmaceuticals initiated with a Buy at Berenberg
- 05/25/22 Raymond James
- NexGen Energy removed from Analyst Current Favorites list at Raymond James
- 04/22/22 Canaccord
- NexGen Energy price target raised to C$10.75 from C$10 at Canaccord
- 04/11/22 RBC Capital
- NexGen Energy upgraded to Outperform from Sector Perform at RBC Capital
- 03/03/22 Raymond James
- NexGen Energy price target raised to C$9 from C$8.50 at Raymond James
IRT Independence Realty Trust - 06/30/22 Jefferies
- Independence Realty Trust price target lowered to $24 from $27 at Jefferies
- 05/10/22 Barclays
- Independence Realty Trust price target lowered to $28 from $30 at Barclays
- 05/09/22 BTIG
- Independence Realty Trust assumed with a Buy at BTIG
- 04/22/22 Jefferies
- Independence Realty Trust initiated with a Buy at Jefferies
- 08/02/22 BofA
- Frontier Group resumed with a Buy at BofA
- 07/12/22 Susquehanna
- Frontier Group price target lowered to $13 from $15 at Susquehanna
- 06/27/22 Evercore ISI
- Frontier Group price target lowered to $15 from $20 at Evercore ISI
- 06/23/22 Raymond James
- Frontier Group upgraded to Outperform from Market Perform at Raymond James
- 06/15/22 Craig-Hallum
- Planet Labs price target lowered to $10 from $15 at Craig-Hallum
- 06/15/22 Needham
- Planet Labs price target lowered to $8.00 from $10.50 at Needham
- 06/15/22 Benchmark
- Planet Labs price target lowered to $11 from $15 at Benchmark
- 05/25/22 Benchmark
- EOCL award watershed moment for BlackSky, GIS industry, says Benchmark
- 08/02/22 Berenberg
- Berenberg downgrades Teladoc to Hold on 'underwhelming execution'
- 08/02/22 Cowen
- Teladoc downgraded to Market Perform from Outperform at Cowen
- 07/29/22 Deutsche Bank
- Teladoc price target lowered to $34 from $44 at Deutsche Bank
- 07/28/22 Stifel
- Teladoc price target lowered to $30 from $36 at Stifel
- 07/29/22 Cowen
- Tilray price target lowered to $9 from $23 at Cowen
- 07/29/22 Benchmark
- Tilray cut to Sell at Benchmark on continued deterioration in core business
- 07/29/22 Benchmark
- Tilray downgraded to Sell from Hold at Benchmark
- 07/15/22 Roth Capital
- Tilray price target lowered to $4 from $8 at Roth Capital
- 05/23/22 Jefferies
- Par Technology price target lowered to $43 from $55 at Jefferies
- 05/17/22 Goldman Sachs
- Par Technology initiated with a Neutral at Goldman Sachs
- 03/02/22 Craig-Hallum
- Par Technology price target lowered to $60 from $100 at Craig-Hallum
- 01/26/22 BTIG
- Par Technology price target lowered to $60 from $110 at BTIG
- $46.56 /
+5.185 (+12.53%) - 08/02/22 Cowen
- TransMedics price target raised to $50 from $45 at Cowen
- 08/02/22 Oppenheimer
- TransMedics price target raised to $45 from $40 at Oppenheimer
- 08/02/22 JPMorgan
- TransMedics upgraded on 'highly attractive' opportunity at JPMorgan
- 08/02/22 Canaccord
- TransMedics price target raised to $58 from $46 at Canaccord
- 08/05/22 JPMorgan
- Natera price target raised to $100 from $80 at JPMorgan
- 07/18/22 Piper Sandler
- Natera CMS decision will drive more tests, says Piper Sandler
- 07/14/22 Piper Sandler
- Piper says Natera selection for UnitedHealth network validates practices
- 05/15/22 Piper Sandler
- Natera price target lowered to $60 from $75 at Piper Sandler
- 06/01/22 DA Davidson
- Proterra initiated with a Buy at DA Davidson
- 05/19/22 Barclays
- Proterra price target lowered to $6 from $8 at Barclays
- 05/16/22 Citi
- Proterra price target lowered to $6.50 from $8.50 at Citi
- 05/13/22 BofA
- Proterra double downgraded to Underperform at BofA
- 07/27/22
- Frontier Group sees Q3 adjusted pre-tax margin between 1%-5%
- 07/27/22
- Frontier Group reports Q2 EPS 6c, consensus 7c
- 04/28/22
- Frontier Group sees Q2 pre-tax margin between 1%-5%
- 04/28/22
- Frontier Group reports Q1 EPS (56c), consensus (43c)
- $46.56 /
+5.185 (+12.53%) - 08/01/22
- TransMedics raises FY22 revenue view to $67M-$75M to $59M-$65M
- 08/01/22
- TransMedics reports Q2 EPS (41c), consensus (35c)
- 05/03/22
- TransMedics raises FY22 revenue view to $59M-$65M from $49M-$55M
- 05/03/22
- TransMedics reports Q1 EPS (38c), consensus (38c)
- 07/28/22
- Tilray reports Q4 EPS (90c) vs. 38c last year
- 04/06/22
- Tilray reports Q3 EPS 9c vs. ($1.03) last year
- 07/27/22
- Teladoc cuts FY22 EPS view to ($62.00)-($61.00) from ($43.50)-($43.00)
- 07/27/22
- Teladoc sees Q3 EPS (85c)-(60c), consensus (55c)
- 07/27/22
- Teladoc reports Q2 EPS ($19.22), consensus (64c)
- 07/27/22
- Notable companies reporting after market close
- 08/04/22
- Shake Shack sees Q3 revenue $221M-$226.5M consensus $245M
- 08/04/22
- Shake Shack reports Q2 EPS 0c vs. 5c last year
- 05/05/22
- Shake Shack reports Q1 adjusted EPS (19c), consensus (22c)
- 02/17/22
- Shake Shack sees Q1 revenue $196M-$201.4M, consensus $210.87M
RXRX Recursion Pharmaceuticals - 03/23/22
- Recursion Pharmaceuticals reports Q4 EPS (38c), consensus (31c)
- 07/28/22
- Roku sees Q3 revenue roughly $700M, consensus $901.73M
- 07/28/22
- Roku reports Q2 EPS (82c), consensus (68c)
- 07/28/22
- Notable companies reporting after market close
- 04/28/22
- Roku backs FY22 revenue growth view of 35% y/y, consensus $3.72B
- 07/28/22
- Royal Caribbean sees Q3 adjusted EPS 5c-25c, consensus 91c
- 07/28/22
- Royal Caribbean reports Q2 adjusted EPS ($2.08), consensus ($2.20)
- 07/27/22
- Notable companies reporting before tomorrow's open
- 08/02/22
- Proterra reports Q2 diluted EPS (38c), consensus (19c)
- 03/01/22
- Proterra reports Q4 EPS (43c), consensus (16c)
- 06/14/22
- Planet Labs sees FY23 revenue $177M-$187M, consensus $181.26M
- 06/14/22
- Planet Labs sees Q2 revenue $41M-$43M, consensus $42.26M
- 06/14/22
- Planet Labs reports Q1 EPS (17c), consensus (15c)
- 08/03/22
- Notable companies reporting after market close
- 08/03/22
- Ping Identity reports Q2 adjusted EPS (34c), consensus (11c)
- 05/04/22
- Ping Identity sees 2022 revenue $332M-$342M, consensus $334.91M
- 05/04/22
- Ping Identity sees Q2 revenue $70M-$75M, consensus $73.58M
- 05/10/22
- Par Technology reports Q1 adjusted EPS (26c), consensus (42c)
- 03/01/22
- Par Technology reports Q4 adjusted EPS (36c), consensus (38c)
- 08/04/22
- Natera raises FY22 revenue view to $805M-$825M from $790M-$810M
- 08/04/22
- Natera reports Q2 EPS ($1.50), consensus ($1.50)
- 05/05/22
- Natera raises 2022 revenue view to $790M-$810M from $770M-$790M
- 05/05/22
- Natera reports Q1 EPS ($1.45), consensus ($1.48)
IRT Independence Realty Trust - 07/27/22
- Independence Realty Trust reports Q2 FFO 26c, consensus 26c
- 05/03/22
- Independence Realty raises FY22 core CCO view to $1.04-$1.06 from $1.00-$1.04
- 05/03/22
- Independence Realty Trust reports Q1 core FFO 25c, consensus 25c
- 02/16/22
- Independence Realty Trust sees FY22 core FFO $1.00-$1.04, consensus 97c
- 05/12/22
- Compass lowers FY22 revenue view to $7.6B-$8.0B from $7.9B-$8.1B
- 05/12/22
- Compass sees Q2 revenue $2.0B-$2.2B, consensus $2.41B
- 05/12/22
- Compass reports Q1 EPS (45c), consensus (48c)
- 02/16/22
- Compass sees Q1 revenue 16.25%-16.75% of FY22 outlook, consensus $1.42B
- 06/24/22
- Carnival expects a net loss for Q3
- 06/24/22
- Carnival reports Q2 EPS ($1.61), consensus ($1.08)
- 06/23/22
- Notable companies reporting before tomorrow's open
|
Hot Stocks
|
Maxar Technologies… Maxar Technologies announced it received a Phase A study contract from NASA for the National Oceanic and Atmospheric Administration's (NOAA) Geostationary Extended Observations (GeoXO) Spacecraft mission. During the ten-month contract, Maxar will develop the spacecraft concept, mature necessary technologies, conduct analysis on robotic servicing and payload accommodations, help define the potential performance, risks, costs and development schedule for a three-satellite, next-generation constellation of weather monitoring satellites. "Maxar is excited to work on designing NOAA's next-generation weather monitoring spacecraft," said Chris Johnson, Maxar Senior Vice President and General Manager of Space. "This contract builds on our legacy of manufacturing the first- and second-generation GOES satellites, which operated beyond their expected lifetimes. Maxar is committed to helping customers use spacecraft and space-based data to study weather patterns and mitigate climate change, and this GeoXO study contract is the next evolution of that work." ShowHide Related Items >><< - 07/12/22
- Volta appoints Michelle Kley as Chief Legal Officer
- 06/24/22
- Mercury Systems enters cooperation agreements with Jana, Starboard
- 05/25/22
- Maxar Technologies trading resumes
- 05/25/22
- NRO awards Maxar ten-year contract under EOCL acquisition
- 06/21/22 Wells Fargo
- Wells Fargo bullish on Maxar Technologies, initiates with an Overweight
- 06/21/22 Wells Fargo
- Maxar Technologies initiated with an Overweight at Wells Fargo
- 05/26/22 JPMorgan
- Maxar contract 'meaningfully positive development,' says JPMorgan
- 05/25/22 Benchmark
- EOCL award watershed moment for BlackSky, GIS industry, says Benchmark
- 05/25/22
- Maxar Technologies tightens 2022 revenue view $1.805B-$1.855B
- 05/09/22
- Maxar Technologies reports Q1 EPS (10c), consensus (5c)
- 02/22/22
- Maxar Technologies reports Q4 EPS 94c, consensus 7c
- 06/21/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 05/25/22
- What You Missed On Wall Street On Wednesday
- 05/17/22
- What You Missed On Wall Street On Tuesday
- 05/17/22
- What You Missed On Wall Street This Morning
- 02/22/22
- Maxar Technologies options imply 11.5% move in share price post-earnings
|
Hot Stocks
|
BlackSky Technology Inc.… BlackSky Technology Inc. (BKSY) and Airbus (EADSY)) have signed a reseller agreement enabling BlackSky to expand its platform's all-weather, day and night, and high-resolution satellite imagery offerings for BlackSky customers. "The combination of BlackSky's dynamic, real-time multi-source Spectra AI monitoring platform with multiple types of very high-resolution electro-optical and synthetic aperture radar images gives customers great flexibility for tasking requests when monitoring fast-moving, day and night operations and sites around the globe," said Brian E. O'Toole, BlackSky CEO. ShowHide Related Items >><< - 08/02/22
- Air Lease announces lease placements for two new Airbus A321neo jets
- 07/27/22
- Airbus now targets deliver around 700 commercial aircraft in 2022
- 07/27/22
- Airbus delays A320 monthly rate production of 65 to early 2024
- 07/21/22
- American Airlines says total debt reduction 'remains a top priority'
- 07/14/22
- BlackSky receives a $4.4M award from IARPA to support 2nd phase of SMART Program
- 06/21/22
- BlackSky awarded up to $241M basic order agreement from JAIC
- 06/15/22
- BlackSky promotes Henry Dubois to CFO
- 05/25/22
- BlackSky says EOCL contract with options valued up to $1.021B
- 07/26/22 Lake Street
- BlackSky initiated with a Buy at Lake Street
- 05/25/22 Benchmark
- EOCL award watershed moment for BlackSky, GIS industry, says Benchmark
- 07/28/22 JPMorgan
- Airbus price target lowered to EUR 175 from EUR 180 at JPMorgan
- 07/28/22 Deutsche Bank
- Airbus price target lowered to EUR 141 from EUR 142 at Deutsche Bank
- 07/13/22 Kepler Cheuvreux
- Airbus upgraded to Buy from Hold at Kepler Cheuvreux
- 06/27/22 Morgan Stanley
- Airbus price target lowered to EUR 135 from EUR 137 at Morgan Stanley
- 07/27/22
- Airbus reports Q2 adjusted EBIT EUR 1.38B vs. EUR 2.01B last year
- 05/05/22
- Airbus reports Q1 revenue EUR 12B, EBIT adjusted EUR 1.3B
- 02/17/22
- Airbus reports 2021 revenue EUR 52.1B, EBIT adjusted EUR 4.9B
- 06/15/22
- BlackSky backs FY22 revenue view of $58M-$62M, one estimate $67.5M
- 05/11/22
- BlackSky maintains 2022 revenue view $58M-$62M, one est. $61.5M
- 05/11/22
- BlackSky reports Q1 EPS (17c) vs. (70c) last year.
- 07/20/22
- Airbus CEO expects supply chain crisis to last until 2023, FT reports
- 07/18/22
- Air Lease close to SEA320neo family jet order, Bloomberg reports
- 07/18/22
- Boeing CEO Calhoun defended his record at the company, FT reports
- 07/17/22
- Airbus, Boeing vie for almost $21B of orders at show, Bloomberg reports
- 07/20/22
- What You Missed On Wall Street This Morning
- 07/13/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 06/15/22
- What You Missed On Wall Street This Morning
- 05/25/22
- What You Missed On Wall Street On Wednesday
|
On The Fly
| ShowHide Related Items >><< - 05/22/22
- Fly Intel: Top five weekend stock stories
- 05/16/22
- Warby Parker reports active customers increased 18.0% to 2.23M in Q1
- 03/17/22
- Warby Parker drops 12% to $23.60 after FY22 revenue guidance misses estimates
- 03/11/22
- Warby Parker announces new partnership with Eastman Chemical
- 05/11/22
- Vacasa reports Q1 gross booking value up 101% to $494M
- 05/05/22
- Vacasa appoints John Banczak as chief strategy officer
- 03/18/22
- Vacasa CEO: We're strong partners with Airbnb, Booking Holdings
- 03/16/22
- Vacasa reports Q4 Nights Sold 1.1M, a 55% year-over-year increase.
- 05/19/22
- Energy Fuels secures rare earth land position in Brazil
- 06/17/22
- Sana presents data at ISSCR 2022 on transplanted allogeneic, hypoimmune cells
- 06/01/22
- Sana Biotechnology announces expected cost savings from facility switch
RXRX Recursion Pharmaceuticals - 07/21/22
- Recursion Pharmaceuticals granted EU orphan drug designation for REC-4881
- 06/20/22
- Recursion announces initiation of Phase 2/3 trial for NF2-Mutated Meningiomas
- 04/11/22
- Recursion Pharmaceuticals granted FDA Fast Track designation for REC-4881
- 03/18/22
- Recursion Pharmaceuticals enrolls first patient in Phase 2 SYCAMORE trial
- 07/21/22
- NOAA contracts with Planet to gain 'situational awareness' of oil spills debris
- 07/19/22
- Planet Labs completes pilot program with Organic Valley
- 07/13/22
- Planet Labs Germany expands collaboration with BKG
- 06/15/22
- Planet Labs falls -17.6%
- 07/15/22
- NexGen Energy announces CNSC acceptance of EIS submission
- 06/21/22
- NexGen Energy announces Rook I Project EIS
- 04/25/22
- NexGen Energy signs IBA with Clearwater River Dene Nation for Rook I Project
- 03/01/22
- NexGen Energy uplists to NYSE from NYSE American
- 07/21/22
- NeoGenomics appoints Chris Smith as CEO
- 07/21/22
- NeoGenomics names Chris Smith CEO
- 06/03/22
- NeoGenomics receives CAP certfication in Suzhou China laboratory
- 05/16/22
- NeoGenomics appoints Lynn Terault as interim CEO
- 05/16/22
- Tiger Global buys Starry, exits Adobe in Q1
- 03/28/22
- Cathie Wood's ARK Investment bought 43.6K shares of Monday.com today
- 03/02/22
- Monday.com announces strategic alliance with KPMG
- 07/06/22
- Lightspeed publishes first sustainability report
- 06/09/22
- Lightspeed, Threedium enter partnership for 3D product visualization
- 06/02/22
- Lightspeed launches new B2B platform
- 05/13/22
- Lightspeed rises 26.8%
- 07/17/22
- Iveric Bio announces post-hoc analysis from GATHER1 clinical trial of Zimura
- 07/06/22
- Iveric bio, DelSiTech announce Zimura global license agreement
- 07/05/22
- Iveric bio, DelSiTech in pact to develop sustained release Zimura
- 06/14/22
- Iveric bio director Roberts purchases 25K in company shares
- 07/28/22
- Enovix enters distribution agreement with EDOM Technology
- 07/12/22
- Enovix announces shipment of battery packs
- 06/28/22
- Enovix Mobility announces it has broadened leadership team
- 06/22/22
- Enovix to join Russell 2000, 3000 Indexes
- 06/29/22 JPMorgan
- Vacasa price target lowered to $6 from $9 at JPMorgan
- 06/09/22 Goldman Sachs
- Vacasa price target lowered to $5.50 from $9 at Goldman Sachs
- 06/09/22 JMP Securities
- Vacasa assumed with an Outperform at JMP Securities
- 03/29/22 KeyBanc
- End-market data analysis suggests consumer travel holding up well, says KeyBanc
- 06/24/22 Cowen
- Enovix price target lowered to $20 from $24 at Cowen
- 05/03/22 Cowen
- Enovix order 'perhaps' from Apple or Google, says Cowen
- 03/04/22 Craig-Hallum
- Enovix price target lowered to $35 from $50 at Craig-Hallum
- 03/04/22 Cowen
- Enovix price target lowered to $29 from $32 at Cowen
- 07/07/22 Morgan Stanley
- Iveric bio price target raised to $30 from $25 at Morgan Stanley
- 06/08/22 Guggenheim
- Iveric bio initiated with a Buy at Guggenheim
- 06/08/22 BofA
- Iveric bio initiated with a Buy at BofA
- 05/12/22 B. Riley
- B. Riley puts Neutral rating on Iveric bio in 'contrarian call'
- 07/08/22 Piper Sandler
- CMS proposal changes little for test companies, says Piper Sandler
- 06/02/22 Piper Sandler
- NeoGenomics initiated with an Overweight at Piper Sandler
- 03/29/22 Cowen
- NeoGenomics price target lowered to $24 from $42 at Cowen
- 03/29/22 BTIG
- NeoGenomics price target lowered to $28 from $35 at BTIG
- 05/25/22 Raymond James
- NexGen Energy removed from Analyst Current Favorites list at Raymond James
- 04/22/22 Canaccord
- NexGen Energy price target raised to C$10.75 from C$10 at Canaccord
- 04/11/22 RBC Capital
- NexGen Energy upgraded to Outperform from Sector Perform at RBC Capital
- 03/03/22 Raymond James
- NexGen Energy price target raised to C$9 from C$8.50 at Raymond James
- 06/15/22 Craig-Hallum
- Planet Labs price target lowered to $10 from $15 at Craig-Hallum
- 06/15/22 Needham
- Planet Labs price target lowered to $8.00 from $10.50 at Needham
- 06/15/22 Benchmark
- Planet Labs price target lowered to $11 from $15 at Benchmark
- 05/25/22 Benchmark
- EOCL award watershed moment for BlackSky, GIS industry, says Benchmark
RXRX Recursion Pharmaceuticals - 04/18/22 BofA
- Recursion Pharmaceuticals downgraded to Neutral from Buy at BofA
- 03/04/22 SVB Securities
- Recursion Pharmaceuticals downgraded to Market Perform from Outperform at SVB Leerink
- 09/21/21 Berenberg
- Recursion Pharmaceuticals initiated with a Buy at Berenberg
- 07/22/22 Piper Sandler
- Warby Parker initiated with an Overweight at Piper Sandler
- 07/21/22 Goldman Sachs
- Warby Parker price target lowered to $12 from $16 at Goldman Sachs
- 07/20/22 Stifel
- Warby Parker price target lowered to $11 from $15 at Stifel
- 06/27/22 Loop Capital
- Warby Parker price target lowered to $15 from $18 at Loop Capital
- 06/03/22 Piper Sandler
- Lightspeed price target raised to $40 from $39 at Piper Sandler
- 05/20/22 TD Securities
- Lightspeed price target lowered to C$60 from C$80 at TD Securities
- 05/20/22 Raymond James
- Lightspeed price target raised to C$43 from C$40 at Raymond James
- 05/20/22 Truist
- Lightspeed price target lowered to $45 from $60 at Truist
- 07/18/22 Piper Sandler
- Monday.com price target lowered to $150 from $200 at Piper Sandler
- 06/01/22 Tigress Financial
- Monday.com price target lowered to $240 from $432 at Tigress Financial
- 05/17/22 Cowen
- Monday.com price target lowered to $200 from $240 at Cowen
- 05/17/22 Canaccord
- Monday.com price target lowered to $150 from $200 at Canaccord
- 05/23/22 Jefferies
- Par Technology price target lowered to $43 from $55 at Jefferies
- 05/17/22 Goldman Sachs
- Par Technology initiated with a Neutral at Goldman Sachs
- 03/02/22 Craig-Hallum
- Par Technology price target lowered to $60 from $100 at Craig-Hallum
- 01/26/22 BTIG
- Par Technology price target lowered to $60 from $110 at BTIG
- 07/28/22 Canaccord
- Energy Fuels initiated with a Speculative Buy at Canaccord
- 05/16/22
- Warby Parker backs FY22 revenue view $650M-$660M, consensus $656.98M
- 05/16/22
- Warby Parker reports Q1 adjusted EPS (30c), consensus 1c
- 03/17/22
- Warby Parker sees 2022 revenue $650M-$660M, consensus $687.75M
- 03/17/22
- Warby Parker reports Q4 adjusted EPS (8c), consensus (9c)
- 05/11/22
- Vacasa backs FY22 revenue view of $1.125B-$1.175B, consensus $1.16B
- 05/11/22
- Vacasa sees Q2 revenue $280M-$290M, consensus $282.5M.
- 05/11/22
- Vacasa reports Q1 EPS (13c), consensus (13c)
- 03/16/22
- Vacasa reports Q4 EPS (6c), consensus (28c)
- 03/16/22
- Sana Biotechnology reports Q4 EPS (65c) vs ($2.98) last year
RXRX Recursion Pharmaceuticals - 03/23/22
- Recursion Pharmaceuticals reports Q4 EPS (38c), consensus (31c)
- 06/14/22
- Planet Labs sees FY23 revenue $177M-$187M, consensus $181.26M
- 06/14/22
- Planet Labs sees Q2 revenue $41M-$43M, consensus $42.26M
- 06/14/22
- Planet Labs reports Q1 EPS (17c), consensus (15c)
- 05/10/22
- Par Technology reports Q1 adjusted EPS (26c), consensus (42c)
- 03/01/22
- Par Technology reports Q4 adjusted EPS (36c), consensus (38c)
- 04/27/22
- NeoGenomics reports Q1 adjusted EPS (20c), consensus (23c)
- 04/26/22
- Notable companies reporting before tomorrow's open
- 03/28/22
- NeoGenomics now sees Q1 revenue below $118M-$120M range, consensus $119.16M
- 05/16/22
- Monday.com raises FY22 revenue view to $488M-$492M from $470M-$475M
- 05/16/22
- Monday.com sees Q2 revenue $117M-$119M, consensus $110.88M
- 05/16/22
- Monday.com reports Q1 EPS (96c), consensus ($1.02)
- 02/23/22
- Monday.com sees FY22 revenue $470M-$475M, consensus $443.1M
- 05/20/22
- Lightspeed sees FY23 revenue of $740M-$760M
- 05/20/22
- Lightspeed sees Q1 revenue of $165M-$170M
- 05/20/22
- Lightspeed reports Q4 adjusted EPS (15c) vs. (10c) a year ago
- 02/02/22
- Lightspeed sees FY22 revenue $540M-$544M, up from $520M-$535M
- 07/26/22
- Iveric bio reports Q2 EPS (42c), consensus (31c)
- 05/04/22
- Iveric bio reports Q1 EPS (29c), consensus (29c)
- 02/24/22
- Iveric bio reports Q4 EPS (29c), consensus (24c)
- 05/11/22
- Enovix reports Q1 EPS (16c), consensus (16c)
- 03/03/22
- Enovix reports Q4 EPS (60c), consensus (15c)
|
Initiation
|
Lake Street analyst… Lake Street analyst Jaeson Schmidt initiated coverage of BlackSky with a Buy rating and $6 price target. BlackSky is addressing the geospatial intelligence portion of the space market with its real-time imagery, data, software, and analytics and "offers investors an open-ended growth story addressing the ramping space economy," Schmidt said. He sees the company's software-first approach and Software-as-a-Service revenue model leading to strong recurring revenue, high gross margins and "significant earnings power," Schmidt added. ShowHide Related Items >><< - 07/14/22
- BlackSky receives a $4.4M award from IARPA to support 2nd phase of SMART Program
- 06/21/22
- BlackSky awarded up to $241M basic order agreement from JAIC
- 06/15/22
- BlackSky promotes Henry Dubois to CFO
- 05/25/22
- BlackSky says EOCL contract with options valued up to $1.021B
- 05/25/22 Benchmark
- EOCL award watershed moment for BlackSky, GIS industry, says Benchmark
- 06/15/22
- BlackSky backs FY22 revenue view of $58M-$62M, one estimate $67.5M
- 05/11/22
- BlackSky maintains 2022 revenue view $58M-$62M, one est. $61.5M
- 05/11/22
- BlackSky reports Q1 EPS (17c) vs. (70c) last year.
- 06/15/22
- What You Missed On Wall Street This Morning
- 05/25/22
- What You Missed On Wall Street On Wednesday
|